Friday, 5 May 2017

Are you the Most Innovative European Biotech SME?

SusChem founding partner EuropaBio is inviting small and medium sized biotech companies (SMEs) across Europe to apply for the 8th edition of its Most Innovative European Biotech SME Award: a unique annual initiative recognising biotech innovation and its contribution to society. SMEs interested in entering the competition are invited to apply by 26 June 2017 via the awards dedicated website.

Three categories are available for entry: healthcare, agricultural or industrial biotechnology. Applications must be submitted online at biotechSMEawards.eu by close of business on 26 June and two companies will be shortlisted in each category by a jury of biotech experts.

The winners will be celebrated during a landmark event for SMEs to held in early October. Each winner will also receive a €10 000 prize and two years free membership of EuropaBio.

In order to be considered for the EuropaBio SME awards a company must qualify as an SME under the standard EU SME definition: the company's primary location of operations must be within Europe, it must employ 250 or less staff, and its annual turnover must be €50 million or less.

Why SMEs?
According to the European Commission, “small and medium-sized enterprises (SMEs) are the backbone of Europe's economy. They represent 90% of all businesses in the EU. In the past five years, they have created around 85% of new jobs and provided two-thirds of the total private sector employment in the EU.” 

In other words, SMEs matter and their leaders in innovation should be recognised and rewarded.

Biotech exemplifies the way in which science and scientific breakthroughs can be applied to respond to society’s current challenges. From new therapies that can address unmet medical needs and fight epidemics and rare diseases, to industrial processes that use renewable feedstocks instead of crude oil, to drought-resistant crops that allow farmers around the world to feed more people under unpredictable climatic conditions, biotechnology pays significant economic, social and environmental dividends.

The awards have become one of the main initiatives in the European biotech calendar, with almost 200 SMEs competing over the years. The success stories from previous winners can be read online at biotechSMEawards.eu.

The jury
The expert jury are all involved in biotech and understand the science, the funding realities and the regulatory and political frameworks in which European biotech SMEs operate. They appreciate the potential of innovation and SMEs for Europe’s future, and they will carefully analyse each application to select the nominees. The jury includes:
  • Peter Heinrich, Chairman of German national biotech association BIO Deutschland and Managing Director of Sinfonie Life Science Management GmbH, Planegg.
  • Frank Bulens, member of the Management Committee and Board of Directors of Capricorn Venture Partners. He is active in diagnostics, therapeutics and medical devices as well as digital health-tech for the various Capricorn funds that are investing in these areas.
  • John Brennan, the new Secretary General of EuropaBio, who takes up his post from 19 June 2017, with over 25 years’ experience both on the regulatory and the industrial sides of the healthcare industry.
Further jury members will be announced before the summer.

Wednesday, 3 May 2017

Water in the Circular Economy: Innovations for Urban Water Treatment

The FP7 project R3Water (Reuse, Recovery and Resource Efficiency: Innovations in Urban wastewater treatment) will be holding its final conference on 30 May 2017 in Brussels. The conference will provide participants with detailed information on the innovations for urban water treatment developed in the project.

The final R3Water project conference entitled ‘Water in the circular economy – innovations for urban water treatment’ will take place from 10:00 on 30 May 2017 at the Representation of the State of Hessen to the EU, 21 Rue Montoyer, 1000 Brussels.

As well as presentations related to the developments made during R3Water, several keynote speakers will give insights on the reuse of water, resource recovery and resource efficiency in urban waste water treatment.



More about R3Water
The R3Water project was funded under the European Commission’s FP7 programme and started in January 2014 for 42 months with a budget of EUR 7.8 million.

Wastewater treatment plants are usually regarded as facilities to avoid emissions from wastewater. Current research and development shows that these plants can be converted and upgraded into production units to provide energy, nutrients, water for re-use and possibly other valuable outputs. This is achieved by improved resource efficiency in the plant as well as through the use of new technologies and business models that allow the re-use of resources from the incoming water.

The main objective of the R3Water project is to demonstrate solutions that support this transition from a treatment plant for urban wastewater to a production unit for different valuable products.

The project consortium, coordinated by IVL Swedish Environmental Research Institute, brings together 12 technological partners from seven European countries.

More information about the R3Water project can be found on the project website and in its brochure.